Barclays’s Neumora Therapeutics NMRA Stock Holding History
Bought
Maintained
Sold
Other funds holding NMRA
SL
Barclays's NMRA Position: Q3 2026 in Review
Barclays increased its Neumora Therapeutics (NMRA) stake by 28% in Q3 2026, buying an estimated $25.6K and bringing the position to 84,730 shares worth $50.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4572.
Barclays first reported a position in NMRA in Q4 2023 and has held it in 12 quarters since. The position peaked at $1.77M in Q4 2024. 127 funds tracked by Wall St. Rank hold NMRA as of Q3 2026.
- Barclays held 84,730 shares of Neumora Therapeutics worth $50.5K as of Q3 2026.
- Barclays bought 18,504 Neumora Therapeutics shares in Q3 2026, an estimated $25.6K.
- Neumora Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4572 holding.
- Barclays first reported a position in Neumora Therapeutics in Q4 2023 and has held it in 12 quarters since.
- Barclays's Neumora Therapeutics position peaked at $1.77M in Q4 2024.
- 127 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q3 2026.
Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.